国内团队：哪些细菌促进TMAO的产生？ | 热心肠日报
肉毒碱饮食干预后氧化三甲胺的产生量有助于个性化营养的实施和微生物特征的识别
10.1186/s40168-020-00912-y
11-19, Article
Abstract & Authors:展开
Abstract:收起
The capability of gut microbiota in degrading foods and drugs administered orally can result in diversified efficacies and toxicity interpersonally and cause significant impact on human health. Production of atherogenic trimethylamine N-oxide (TMAO) from carnitine is a gut microbiota-directed pathway and varies widely among individuals. Here, we demonstrated a personalized TMAO formation and carnitine bioavailability from carnitine supplements by differentiating individual TMAO productivities with a recently developed oral carnitine challenge test (OCCT). By exploring gut microbiome in subjects characterized by TMAO producer phenotypes, we identified 39 operational taxonomy units that were highly correlated to TMAO productivity, including Emergencia timonensis, which has been recently discovered to convert γ-butyrobetaine to TMA in vitro. A microbiome-based random forest classifier was therefore constructed to predict the TMAO producer phenotype (AUROC = 0.81) which was then validated with an external cohort (AUROC = 0.80). A novel bacterium called Ihubacter massiliensis was also discovered to be a key microbe for TMA/TMAO production by using an OCCT-based humanized gnotobiotic mice model. Simply combining the presence of E. timonensis and I. massiliensis could account for 43% of high TMAO producers with 97% specificity. Collectively, this human gut microbiota phenotype-directed approach offers potential for developing precision medicine and provides insights into translational research.
First Authors:
Wei-Kai Wu
Correspondence Authors:
Ming-Shiang Wu
All Authors:
Wei-Kai Wu,Suraphan Panyod,Po-Yu Liu,Chieh-Chang Chen,Hsien-Li Kao,Hsiao-Li Chuang,Ying-Hsien Chen,Hsin-Bai Zou,Han-Chun Kuo,Ching-Hua Kuo,Ben-Yang Liao,Tina H T Chiu,Ching-Hu Chung,Angela Yu-Chen Lin,Yi-Chia Lee,Sen-Lin Tang,Jin-Town Wang,Yu-Wei Wu,Cheng-Chih Hsu,Lee-Yan Sheen,Alexander N Orekhov,Ming-Shiang Wu